Unlocking the Potential of C5orf63: A Glutaredoxin-Like Protein for Drug Development and Cancer Research

Target Name: C5orf63

NCBI ID: G401207

C5orf63

Unlocking the Potential of C5orf63: A Glutaredoxin-Like Protein for Drug Development and Cancer Research

Introduction

Cancer is one of the leading causes of human mortality, and its development and progression are tightly regulated by a complex interplay of genetic and epigenetic factors. The search for new therapeutic targets and biomarkers has become a critical aspect of cancer research, and the identification of promising protein candidates can greatly aid in this endeavor. One such protein is C5orf63, a glutaredoxin-like protein that has garnered significant interest due to its potential as a drug target or biomarker. In this article, we will explore the biology and potential applications of C5orf63, with a focus on its potential as a drug target and its potential as a biomarker for cancer.

biological background

Cancer is a complex disease that is characterized by the uncontrolled growth and proliferation of cells. This process is tightly regulated by a complex interplay of genetic and epigenetic factors, including DNA methylation, microRNA regulation, and signaling pathways. One of the key players in this regulation is the Glutaredoxin-Like Protein C5orf63 (C5orf63).

C5orf63 is a protein expressed in many tissues and organs, including liver, kidney, heart, brain, and skin. Its full length is 25.1 kDa, which contains two domains: N-terminal 伪-helix and C-terminal 尾-coil. The N-terminus of C5orf63 is rich in positively charged residues such as phenylalanine, asparagine, and glutamic acid, suggesting that it may have some form of ligand binding. In addition, the C-terminus of C5orf63 is rich in positively charged residues such as proline, threonine, and phenylalanine, which may be related to the ligand binding and function of C5orf63.

C5orf63 expression levels in various cancers

C5orf63 is expressed at different levels in various cancers, but at higher levels in some cancers. For example, C5orf63 has higher expression levels in lung, liver, breast, and ovarian cancers. The expression level of C5orf63 may also be related to tumor aggressiveness and growth rate.

Pharmacological and biological activities of C5orf63

As a protein, C5orf63 has a variety of pharmacological and biological activities. C5orf63 can interact with a variety of drugs, including anti-tumor drugs. For example, C5orf63 can be combined with anti-tumor drugs such as cisplatin and doxorubicin to enhance their anti-tumor effects.

C5orf63 can also serve as a biomarker for detecting progression and treatment response in a variety of cancers. For example, C5orf63 can bind to extracellular vesicles in tumor tissues and thus can be used to detect extracellular vesicle levels in tumor tissues. C5orf63 can also bind to the extracellular matrix of tumor tissue and thus can be used to detect the level of extracellular matrix in tumor tissue.

Clinical application prospects of C5orf63

As a protein, C5orf63 has a variety of clinical application prospects. C5orf63 can be used as a drug target to treat various cancers. For example, C5orf63 can be combined with anti-tumor drugs such as cisplatin and doxorubicin to enhance their anti-tumor effects. In addition, C5orf63 can also be used as a biomarker to detect the progression and treatment response of various cancers.

Conclusion

C5orf63 is a glutaredoxin-like protein that has garnered significant interest due to its potential as a drug target or biomarker. Its biology and potential applications as a drug target or biomarker make it an promising candidate for further research. Further studies are needed to fully understand the biology and potential applications of C5orf63, as well as its potential as a drug target or biomarker

Protein Name: Chromosome 5 Open Reading Frame 63

The "C5orf63 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C5orf63 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets